Jannemarie A M de Ridder1, Eric P van der Stok2, Leonie J Mekenkamp3, Bastiaan Wiering4, Miriam Koopman5, Cornelis J A Punt3, Cornelis Verhoef2, Johannes H de Wilt6. 1. Department of Surgical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: jannemarie.deridder@radboudumc.nl. 2. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 3. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Surgery, Slingeland Hospital, Doetinchem, The Netherlands. 5. Department of Medical Oncology, University Medical Center Utrecht, The Netherlands. 6. Department of Surgical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
OBJECTIVE: To evaluate and compare the overall survival (OS) in case-matched patient groups treated either with systemic therapy or surgeryfor colorectal liver metastases (CRLM). METHODS:Patients with CRLM, without extra-hepatic disease, treated with chemotherapy with or without targeted therapy in two phase III studies (n = 480) were selected and case-matched to patients who underwent liver resection (n = 632). Matching criteria were sex, age, established prognostic factors for survival (clinical risk score). Available computed tomography (CT)-scans of patients treated with systemic therapies were reviewed by three independent liver surgeons for resectability. Survival was compared between patients with resectable CRLM (based on CT-scan review) who were treated withsystemic therapy versus patients who underwent liver resection. RESULTS: A total of 96 patients treated with systemic therapy were included. Pre-treatment CT-scans of the liver were available for review in 56 of the systemically treated patients, and metastases were unanimously considered resectable in 36 patients (64.3%) (complex resectable: n = 25; 69%). These 36 patients were case-matched with 36 patients who underwentliver resection (wedge resection or segmentectomy: n = 26; 72%). Median OS in the patient group treated with systemic therapy was 26.5 months (range 0-81 months), which was significantly lower than that in case-matched patients who underwent liver resection (median OS 56 months; range 6-116) (p = 0.027). CONCLUSIONS: In this case-matched control study, surgery provided superior OS rates compared to systemic therapy for CRLM. Resection of CRLM should always be considered, preferably in a dedicated liver centre, since not all patients that qualify for resection are identified as such.
RCT Entities:
OBJECTIVE: To evaluate and compare the overall survival (OS) in case-matched patient groups treated either with systemic therapy or surgery for colorectal liver metastases (CRLM). METHODS:Patients with CRLM, without extra-hepatic disease, treated with chemotherapy with or without targeted therapy in two phase III studies (n = 480) were selected and case-matched to patients who underwent liver resection (n = 632). Matching criteria were sex, age, established prognostic factors for survival (clinical risk score). Available computed tomography (CT)-scans of patients treated with systemic therapies were reviewed by three independent liver surgeons for resectability. Survival was compared between patients with resectable CRLM (based on CT-scan review) who were treated with systemic therapy versus patients who underwent liver resection. RESULTS: A total of 96 patients treated with systemic therapy were included. Pre-treatment CT-scans of the liver were available for review in 56 of the systemically treated patients, and metastases were unanimously considered resectable in 36 patients (64.3%) (complex resectable: n = 25; 69%). These 36 patients were case-matched with 36 patients who underwent liver resection (wedge resection or segmentectomy: n = 26; 72%). Median OS in the patient group treated with systemic therapy was 26.5 months (range 0-81 months), which was significantly lower than that in case-matched patients who underwent liver resection (median OS 56 months; range 6-116) (p = 0.027). CONCLUSIONS: In this case-matched control study, surgery provided superior OS rates compared to systemic therapy for CRLM. Resection of CRLM should always be considered, preferably in a dedicated liver centre, since not all patients that qualify for resection are identified as such.
Authors: Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers Journal: Nat Rev Clin Oncol Date: 2016-12-20 Impact factor: 66.675
Authors: Nina J Wesdorp; Ruby Kemna; Jaap Stoker; Geert Kazemier; Karen Bolhuis; Jan H T M van Waesberghe; Irene M G C Nota; Femke Struik; Ikrame Oulad Abdennabi; Saffire S K S Phoa; Susan van Dieren; Martinus J van Amerongen; Thiery Chapelle; Cornelis H C Dejong; Marc R W Engelbrecht; Michael F Gerhards; Dirk Grünhagen; Thomas M van Gulik; John J Hermans; Koert P de Jong; Joost M Klaase; Mike S L Liem; Krijn P van Lienden; I Quintus Molenaar; Gijs A Patijn; Arjen M Rijken; Theo M Ruers; Cornelis Verhoef; Johannes H W de Wilt; Rutger-Jan Swijnenburg; Cornelis J A Punt; Joost Huiskens Journal: Radiol Imaging Cancer Date: 2022-05
Authors: Frederike A B Grimme; Maarten F J Seesing; Richard van Hillegersberg; Frits van Coevorden; Koert P de Jong; Iris D Nagtegaal; Cornelis Verhoef; Johannes H W de Wilt Journal: Dig Surg Date: 2018-09-25 Impact factor: 2.588
Authors: D J Höppener; P M H Nierop; E Herpel; N N Rahbari; M Doukas; P B Vermeulen; D J Grünhagen; C Verhoef Journal: Clin Exp Metastasis Date: 2019-05-27 Impact factor: 5.150
Authors: Gang Deng; Hui Li; Gui-Qing Jia; Dan Fang; You-Yin Tang; Jie Xie; Ke-Fei Chen; Zhe-Yu Chen Journal: Cancer Med Date: 2019-08-28 Impact factor: 4.452
Authors: Diederik J Höppener; Pieter M H Nierop; Joost Hof; Kostandinos Sideras; Guoying Zhou; Lydia Visser; Annette S H Gouw; Koert P de Jong; Dave Sprengers; Jaap Kwekkeboom; Peter B Vermeulen; Dirk J Grünhagen; Cornelis Verhoef Journal: Br J Cancer Date: 2020-05-18 Impact factor: 7.640
Authors: Philipp Kron; Michael Linecker; Robert P Jones; Giles J Toogood; Pierre-Alain Clavien; J P A Lodge Journal: Front Oncol Date: 2019-10-16 Impact factor: 6.244